Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche CEO Thomas Schinecker: “Our strong sales growth in the first half of 2024 reflects the high demand for our innovative medicines and diagnostics. In the second quarter, we saw an acceleration o
David Roche says he doesn't believe Kamala Harris can beat Donald Trump
09:00am, Tuesday, 23'rd Jul 2024
David Roche, president and global strategist at Quantum Strategy, explains why he doesn't think Kamala Harris, can beat Republican nominee Donald Trump, if she receives the Democratic presidential nom
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
05:48am, Tuesday, 23'rd Jul 2024
Roche's CT-996 pill could be a promising oral therapy to help individuals lose weight. Roche also has another injectable obesity drug in its pipeline that could potentially be best in class.
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
10:00am, Monday, 22'nd Jul 2024
Roche's latest data update indicates one of its weight-loss programs is doing well. It has more than enough resources to bring its candidate to the market.
Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
08:00am, Monday, 22'nd Jul 2024
The stock price of Roche (OTCMKTS: RHHBY) is up 10% in a week, compared to around a 10% fall for its peer Eli Lilly stock (NYSE: LLY) over this period. The rise in Roche stock in recent days can prima
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
05:59am, Monday, 22'nd Jul 2024
Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
11:21am, Thursday, 18'th Jul 2024
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
07:20am, Thursday, 18'th Jul 2024
Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for the
Mizuho's Jared Holz talks Roche shares surging on GLP-1 data
06:36pm, Wednesday, 17'th Jul 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk stock movement in the healthcare space on Roche's oral GLP-1 data.
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
01:21pm, Wednesday, 17'th Jul 2024
Roche's Genentech subsidiary is developing a pill-based diabetes and weight loss drug called CT-996. The new GLP-1 drug is in phase 1 clinical trials and saw patients losing 7% of their weight in four
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met al
Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study.1 The study met all primary endpoints, showing that Vabysmo® (faricimab)
Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise
10:45am, Wednesday, 17'th Jul 2024
A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and N
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
09:56am, Wednesday, 17'th Jul 2024
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?
09:53am, Wednesday, 17'th Jul 2024
The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roch
